RxDoctor Payments Data

Tony Tran, MD

Family Medicine · Stockton, CANPI 1194949818

Payments from drug & device makers

$1,481in general payments, 2019–2025

Across 57 payments — averaging $25.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$503
  • Amgen$237
  • Actelion Pharmaceuticals US, Inc.$142
  • GSK$136
  • Bayer$103
  • Alkermes, Inc.$70
  • plus $289 from 11 others

What the payments were for

  • Food & beverage$1,481100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,481 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$146,493
Medicare patients
624
Services billed
2,267

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol119$123,376
JardianceEmpagliflozin106$103,210
JanuviaSitagliptin Phosphate77$72,540
KerendiaFinerenone58$57,494
ProliaDenosumab25$41,092
Diclofenac Sodium196$22,673
VascepaIcosapent Ethyl48$22,175
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$19,560
DapagliflozinDapagliflozin Propanediol27$18,536
OzempicSemaglutide17$18,126
TradjentaLinagliptin22$17,135
MyrbetriqMirabegron21$8,875
AlogliptinAlogliptin Benzoate15$6,287
Cyclosporine16$5,064
Albuterol Sulfate HfaAlbuterol Sulfate174$4,968

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$503$123,376119 claims
MerckJanuvia$13$72,54077 claims
BayerKerendia$103$57,49458 claims
AmgenProlia$237$41,09225 claims
GSKTrelegy Ellipta$136$19,56030 claims
Novo NordiskOzempic$53$18,12617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in Stockton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →